Kwon, E D, Drake, C G, Scher, H I, Fizazi, K, Bossi, A, van den Eertwegh, A J M, Krainer, M, Houede, N, Santos, R, Mahammedi, H, Ng, S, Maio, M, Franke, F A, Sundar, S, Agarwal, N, Bergman, A M, Ciuleanu, T E, Korbenfeld, E, Sengeløv, L, Hansen, S, Logothetis, C, Beer, T M, McHenry, M B, Gagnier, P, Liu, D, Gerritsen, W R & CA184-043 Investigators 2014, ' Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial ', Lancet Oncology, vol. 15, no. 7, pp. 700-712 . https://doi.org/10.1016/S1470-2045(14)70189-5 Kwon, E D, Drake, C G, Scher, H I, Fizazi, K, Bossi, A, van den Eertwegh, A J M, Krainer, M, Houede, N, Santos, R, Mahammedi, H, Ng, S, Di Maio, M, Franke, F A, Sundar, S, Agarwal, N, Bergman, A M, Ciuleanu, T E, Korbenfeld, E, Sengelov, L, Hansen, S, Logothetis, C, Beer, T M, McHenry, M B, Gagnier, P, Liu, D & Gerritsen, W 2014, ' Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial ', Lancet Oncology, vol. 15, no. 7, pp. 700-712 . https://doi.org/10.1016/S1470-2045(14)70189-5 Lancet Oncology, 15, 7, pp. 700-12 Lancet Oncology, 15(7), 700-712. Lancet Publishing Group Lancet Oncology Lancet Oncology, Elsevier, 2014, 15, pp.700--12. ⟨10.1016/S1470-2045(14)70189-5⟩ Lancet Oncology, 15, 700-12